Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
Chemoprevention of colorectal cancer: Two steps forward, one step back?
Elizabeth E. Half,
Nadir Arber
*
*
Corresponding author for this work
Sheba Medical Center at Tel Hashomer
Tel Aviv Sourasky Medical Center
Research output
:
Contribution to journal
›
Article
›
peer-review
11
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Chemoprevention of colorectal cancer: Two steps forward, one step back?'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Colorectal Cancer
100%
Celecoxib
100%
Step-back
100%
Chemoprevention
100%
Adenoma
50%
High-risk Individuals
50%
Familial Adenomatous Polyposis
50%
Chemopreventive
50%
Adenomatous Polyps
50%
Highly Effective
25%
Survival Rate
25%
Oncogenesis
25%
Poor Survival
25%
Adherence to Guidelines
25%
Cyclooxygenase-2 Inhibitors
25%
Cancer-related
25%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
25%
Clinical High Risk
25%
Colonoscopy
25%
Sulindac
25%
Cancer Causes
25%
Western World
25%
Low Compliance
25%
Precancerous Lesions
25%
Carcinogenic Mechanism
25%
Polyp Regression
25%
Colonic Adenoma
25%
Surveillance Strategy
25%
Cardiovascular Toxicity
25%
Rofecoxib
25%
Vioxx
25%
Adenoma Recurrence
25%
Screening Effort
25%
Medicine and Dentistry
Celecoxib
100%
Colorectal Carcinoma
100%
Chemoprophylaxis
100%
Adenoma
75%
Clinical Study
50%
Recurrent Disease
50%
Familial Adenomatous Polyposis
50%
Tubular Adenoma
50%
Rofecoxib
50%
Malignant Neoplasm
25%
Survival Rate
25%
Carcinogenesis
25%
Cyclooxygenase 2 Inhibitor
25%
Polyp
25%
Cancer
25%
Colonoscopy
25%
Sulindac
25%
Nonsteroid Antiinflammatory Agent
25%
Precancerous Condition
25%
Colon Adenoma
25%
Cardiovascular Toxicity
25%
Diseases
25%
Pharmacology, Toxicology and Pharmaceutical Science
Celecoxib
100%
Colorectal Carcinoma
100%
Adenoma
75%
Recurrent Disease
50%
Clinical Study
50%
Familial Adenomatous Polyposis
50%
Adenomatous Polyp
50%
Chemopreventive Agents
50%
Rofecoxib
50%
Malignant Neoplasm
25%
Carcinogenesis
25%
Polyp
25%
COX-2 Inhibitor
25%
Non-Steroidal Anti-Inflammatory Drug
25%
Survival Rate
25%
Sulindac
25%
Precancer
25%
Colon Adenoma
25%
Cardiovascular Toxicity
25%
Diseases
25%